Picture courtesy ph.news.yahoo.com
Hong Kong: Two Chinese COVID-19 vaccine candidates, specifically developed to target the Omicron variant of coronavirus, have been approved for clinical trials as boosters in Hong Kong, Reuters reported.
The vaccines have been developed by units of China National Biotec Group (CNBG), according to Sinopharm subsidiary.
Both vaccine candidates contain inactivated or ‘killed’ Omicron virus and are similar to the two Sinopharm vaccines being used in China. They will be tested in adults who have already received two or three vaccine doses, CNBG said in a statement.
A study in China showed that a fourth dose of Sinopharm’s vaccine BBIBP-CorV did not significantly raise antibody levels against Omicron when administered six months after a third booster dose.
Scientists around the world are studying upgraded injections against Omicron, as vaccines based on earlier strains have not been very effective in neutralizing the highly transmissible variant.
New Delhi: Prime Minister Narendra Modi hailed Team India’s thrilling ICC Champions Trophy triumph in… Read More
Rourkela: A resident of Rajgangpur in Odisha's Sundargarh district allegedly fell victim to fraud and… Read More
Bhubaneswar, Chief Minister Mohan Charan Majhi on Sunday inaugurated 16 projects worth about Rs 42… Read More
Dubai: India flirted with danger before managing to hold their nerves and cross the line… Read More
Bhubaneswar: The Shakti application will prove to be a game-changer in ensuring the safety of women… Read More
Bhubaneswar: Shooting of S S Rajamouli's much-anticipated 'SSMB29', featuring Mahesh Babu and Priyanka Chopra, is… Read More
This website uses cookies.
